Mayo Clinic researchers have identified new scoring criteria allowing for the detection of treatable forms of rapidly progressive dementia (RPD) with reasonably high confidence during a patient’s first clinical visit. This scoring criteria may allow physicians to substantially reduce the time it takes to begin treatment. The findings are published in the Annals of Neurology.
Recent Posts
- Interviews of 2025: The Big Issues
- Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy
- To Bring Cell Culture into the Future, Consider Microenvironments
- UC Irvine receives $12 million to test novel stem cell therapy for Huntington’s disease
- Novel surgical approach for retinal gene therapy shows promise


